α-Synuclein-IN-20
α-Synuclein-IN-20 is an inhibitor of α-synuclein (α-Synuclein) with an IC50 of 4.1 μM against human α-Syn. α-Synuclein-IN-20 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-20 scavenges ROS, protects and repairs dopaminergic neurons, ameliorates Parkinson's disease-like symptoms, and shows low cytotoxicity. α-Synuclein-IN-20 can be used for research related to Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 2883627-67-4
- Formula: C22H14F2N2O4
- Molecular Weight:408.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
α-Synuclein-IN-20 (compound 3ea) (30 μM; 72 h) potently inhibits the aggregation of purified human α-synuclein in vitro, with an AIR of 94.7%[1].
α-Synuclein-IN-20 (0-100 μM) dose-dependently inhibits the aggregation of purified human α-synuclein, with an IC50 of 4.1 μM, and exhibits strong activity at a concentration of 100 μM[1].
α-Synuclein-IN-20 (30 μM; 72 h) stabilizes the random coil secondary structure of purified human α-synuclein monomers and inhibits the formation of β-sheet-rich aggregates[1].
α-Synuclein-IN-20 (30 μM; 96 h) slows the aggregation kinetics of purified human α-synuclein, reducing the fiber growth rate constant to 0.271 h−1. Its inhibitory effect is mainly achieved by reducing the formation of oligomeric nuclei during the lag phase[1].
α-Synuclein-IN-20 (30 μM; 88 h) inhibits the formation of dense, cross-linked α-synuclein fibrils, and only produces short, sparse aggregates after incubation with purified human α-synuclein[1].
α-Synuclein-IN-20 (30 μM; added at 21 h, 33 h, or 45 h, with total incubation up to 88 h) dissociates preformed purified human α-synuclein aggregates and inhibits their re-aggregation, with the highest potency when added during the aggregation lag phase[1].
α-Synuclein-IN-20 (10 μM; 48 h post-transfection) significantly inhibits the formation of α-synuclein inclusions in human glioma H4 cells transfected with △155 and SNCAIP plasmids[1].
α-Synuclein-IN-20 (3-10 μM; 30 min) scavenges reactive oxygen species (ROS) in human glioma H4 cells in a dose-dependent manner in vitro, with significant activity observed at the concentration of 10 μM[1].
α-Synuclein-IN-20 (1-1000 μM; 24 h) exhibits low cytotoxicity in human glioma H4 cells and human neuroblastoma SH-SY5Y cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human neuroglioma H4 cells, human neuroblastoma SH-SY5Y cells
-
Concentration:1, 3, 10, 30, 100, 300, 500 and 1000 μM
-
Incubation Time:24 h
-
Result:Showed no significant cytotoxicity in H4 or SH-SY5Y cells.
Maintained cell viability exceeding 85% even at 100 μM.
Chemical Information
-
CAS No. 2883627-67-4
-
Molecular Weight 408.35
-
Formula C22H14F2N2O4
-
SMILES
O=C(C1=C(C=C(C=C1)F)F)NC2=CC=C(C=C2)NC(/C=C/C(C(C=C3)=O)=CC3=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)